Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Trial Profile

Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary) ; DTaP-hepatitis B vaccine; Hepatitis B vaccine recombinant; Measles virus vaccine live; Pneumococcal 11-valent vaccine conjugate; Poliovirus vaccine live oral; RIX 4414; Yellow fever vaccine
  • Indications Diphtheria; Hepatitis B; Measles; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus; Yellow fever
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

Most Recent Events

  • 22 Mar 2017 Status changed from active, no longer recruiting to completed.
  • 05 Oct 2012 Planned end date changed from 1 Feb 2017 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
  • 05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top